The
tumor targeting properties of a new
drug carrier synthesized by bioconjugation of
folic acid (FA) to
beta-cyclodextrins through a poly(
ethylene glycol) (PEG) spacer (CD-PEG-FA) were investigated. Surface plasmon resonance demonstrated that CD-PEG-FA specifically interacts with immobilized
folate binding protein (FBP) while the naked
beta-cyclodextrins do not display any specific interaction. In vitro studies demonstrated that CD-PEG-FA was devoid of cell toxicity. [(3)H]-
folic acid/CD-PEG-FA competition binding investigations performed with
folate receptor overexpressing human epidermal
carcinoma KB cells showed that CD-PEG-FA had about 14 times lower
tumor cell binding capacity than free
folic acid. The carrier cell trafficking properties were investigated using
rhodamine-B as
fluorescent probe, which possesses 3000 and 4580 M(-)(1) inclusion constants for CD-PEG-FA and
beta-cyclodextrins, respectively. Cell-associated fluorescence measurements showed that CD-PEG-FA does not promote the
rhodamine-B uptake into non-
folate receptor expressing human lung
carcinoma MCF7 cells while 19% higher accumulation in KB cells was found with respect to
rhodamine-B loaded
beta-cyclodextrins. Confocal
laser scanning microscopy indicated the presence of cytosolic red fluorescent spots after 2 h of incubation of KB cells with
rhodamine-B included CD-PEG-FA. The
fluorescent dye resided primarily in small spots, namely, endosomes and multivesicular bodies. At 1 h after pulsed incubation, wider red fluorescent cellular structures appeared as a fusion of previous structures.